Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ludovic Samalin

Showing results (1-10 of 122) with videos related to

Pageof 13
Sort By:
L'Encephale|August 24, 2025
Embracing digital psychiatry: Readiness or resistance?Ludovic Samalin
International Journal of Psychiatry in Clinical Practice|November 30, 2011
Atypical antipsychotic-induced mania/hypomania: a review of recent case reports and clinical studiesAmine Benyamina, Ludovic Samalin
L'Encephale|May 1, 2023
[Recommandations to facilitate the discontinuation of valproate in women of childbearing age]Ludovic Samalin, Raoul Belzeaux
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 29, 2023
Why does non-adherence to treatment remain a leading cause of relapse in patients with bipolar disorder?Ludovic Samalin, Raoul Belzeaux
Expert Review of Neurotherapeutics|April 9, 2016
Management of inter-episodic periods in patients with bipolar disorderLudovic Samalin, Andrea Murru, Eduard Vieta
Therapeutics and Clinical Risk Management|July 15, 2011
Clinical potential of lurasidone in the management of schizophreniaLudovic Samalin, Marion Garnier, Pierre-Michel Llorca
Expert Review of Neurotherapeutics|August 7, 2014
Quetiapine extended release for the treatment of bipolar disorderLudovic Samalin, Aurore Tremey, Pierre-Michel Llorca
Therapeutic Advances in Chronic Disease|January 24, 2013
Asenapine in bipolar I disorder: evidence and place in patient managementLudovic Samalin, Thomas Charpeaud, Pierre-Michel Llorca
L'Encephale|February 12, 2013
[Mixed states]Pierre-Michel Llorca, Thomas Charpeaud, Ludovic Samalin
Expert Review of Neurotherapeutics|February 1, 2024
Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adultsLudovic Samalin, Ludivine Boudieu, Pierre Michel Llorca
Pageof 13

Showing results (1-10 of 122) with videos related to

Sort By:
Pageof 13
L'Encephale|August 24, 2025
Embracing digital psychiatry: Readiness or resistance?Ludovic Samalin
International Journal of Psychiatry in Clinical Practice|November 30, 2011
Atypical antipsychotic-induced mania/hypomania: a review of recent case reports and clinical studiesAmine Benyamina, Ludovic Samalin
L'Encephale|May 1, 2023
[Recommandations to facilitate the discontinuation of valproate in women of childbearing age]Ludovic Samalin, Raoul Belzeaux
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 29, 2023
Why does non-adherence to treatment remain a leading cause of relapse in patients with bipolar disorder?Ludovic Samalin, Raoul Belzeaux
Expert Review of Neurotherapeutics|April 9, 2016
Management of inter-episodic periods in patients with bipolar disorderLudovic Samalin, Andrea Murru, Eduard Vieta
Therapeutics and Clinical Risk Management|July 15, 2011
Clinical potential of lurasidone in the management of schizophreniaLudovic Samalin, Marion Garnier, Pierre-Michel Llorca
Expert Review of Neurotherapeutics|August 7, 2014
Quetiapine extended release for the treatment of bipolar disorderLudovic Samalin, Aurore Tremey, Pierre-Michel Llorca
Therapeutic Advances in Chronic Disease|January 24, 2013
Asenapine in bipolar I disorder: evidence and place in patient managementLudovic Samalin, Thomas Charpeaud, Pierre-Michel Llorca
L'Encephale|February 12, 2013
[Mixed states]Pierre-Michel Llorca, Thomas Charpeaud, Ludovic Samalin
Expert Review of Neurotherapeutics|February 1, 2024
Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adultsLudovic Samalin, Ludivine Boudieu, Pierre Michel Llorca
Pageof 13